Literature DB >> 11513761

The fraction of inspired oxygen in infants receiving oxygen via nasal cannula often exceeds safe levels.

J W Kuluz1, G E McLaughlin, B Gelman, G P Cantwell, J Thomas, T Mahon, C L Schleien.   

Abstract

OBJECTIVE: Measure the fraction of inspired oxygen (F(IO(2))) in infants receiving supplemental oxygen via nasal cannula and identify clinical variables that affect F(IO(2)).
METHODS: Hypopharyngeal gas samples were obtained from 20 infants receiving oxygen via nasal cannula at flows between 0 and 4 L/min. F(IO(2)) was calculated using the alveolar gas equation and measurements of partial pressure of oxygen in the samples and the barometric pressure.
RESULTS: F(IO(2)) increased as oxygen flow was increased. F(IO(2)) exceeded safe levels (> 60%) in two thirds of samples when the oxygen flow was 2 L/min or higher. Tachypnea (respiratory rate > 40 breaths/min) was associated with lower F(IO(2)).
CONCLUSION: Infants receiving oxygen via nasal cannula at > or = 2 L/min may be at risk for hyperoxic lung injury. Therefore, we recommend using the lowest possible oxygen flow needed to maintain normoxia in infants requiring prolonged oxygen therapy via nasal cannula.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513761

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  3 in total

1.  Accuracy of a novel system for oxygen delivery to small children.

Authors:  Matthew Coghill; Namasivayam Ambalavanan; Robert L Chatburn; Patricia L Hibberd; Linda L Wright; Waldemar A Carlo
Journal:  Pediatrics       Date:  2011-07-04       Impact factor: 7.124

Review 2.  Oxygen administration in infants.

Authors:  B Frey; F Shann
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-03       Impact factor: 5.747

3.  Evaluation of an innovative low flow oxygen blender system for global access.

Authors:  Ellie Ng; Michelle Dundek; Thomas F Burke
Journal:  Front Pediatr       Date:  2022-09-12       Impact factor: 3.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.